stockrow
Sunday 8 November 2026
Export SVA’s income statement to Excel — free account
Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
6.47
0.00
0.00%
Follow SVA
Alert me
Sinovac Biotech, Ltd. (SVA) P/E ratio
As of 14 October 2026, Sinovac Biotech, Ltd. (SVA) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (June 2017) to 300× (August 2015); the current reading is higher than 61% of that period.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.2× | 0.00% |
| FY2024 | 0.2× | 0.00% |
| FY2023 | 0.2× | 149.27% |
| FY2022 | 0.1× | 0.80% |
| FY2021 | 0.1× | (98.76%) |
| FY2020 | 6.0× | (62.62%) |
| FY2019 | 16.2× | (18.19%) |
| FY2018 | 19.8× | 45.46% |
| FY2017 | 13.6× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.2× | 149.27% |
| Dec 2022 | 0.1× | 5.59% |
| Jun 2022 | 0.1× | (4.54%) |
| Dec 2021 | 0.1× | (39.16%) |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 300×
Ten-year median
0.2×
Current reading's percentile
61
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SVA Sinovac Biotech, Ltd. | 0.2× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)